AstraZeneca's Evusheld Recommended for EU Approval for Covid-19 Prevention
24 März 2022 - 7:44PM
Dow Jones News
By Jaime Llinares Taboada
AstraZeneca PLC said Thursday that its Evusheld drug for
Covid-19 prevention has been recommended for marketing
authorization in the European Union.
The pharmaceutical company said that the Committee for Medicinal
Products for Human Use of the European Medicines Agency based its
positive opinion on Evusheld trial results which showed a 77%
reduction in the risk of developing symptomatic Covid-19 at primary
analysis.
People not adequately protected by a Covid-19 vaccine may
particularly benefit from pre-exposure prophylaxis with Evusheld,
AstraZeneca said.
"Evusheld has the potential to provide long-lasting protection
to vulnerable populations such as the immunocompromised who can't
mount an adequate response to a Covid-19 vaccine, and we'll
continue to work with governments in Europe to make Evusheld
available as quickly as possible," Hugh Montgomery, Professor of
Intensive Care Medicine at University College London, said.
AstraZeneca expects that the European Commission will shortly
complete its review of the positive opinion to determine whether to
grant a marketing authorization for Evusheld.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com
(END) Dow Jones Newswires
March 24, 2022 14:29 ET (18:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024